144
Participants
Start Date
January 31, 2012
Primary Completion Date
January 31, 2018
Study Completion Date
January 31, 2018
degarelix
Starting dose of 240 mg (40 mg/mL; injection volume 2 x 3 mL; s.c.) degarelix one-month depot will be administered sc on Day 0, followed by a maintenance dose of 80 mg (20 mg/mL; injection volume 1 x 4 mL; s.c.) sc degarelix one-month depot will be administered into the anterior abdominal wall on Month 1, 2, 3, 4, 5, 6, 7, 8 and 9 for the 10 month arm and month 1, 2 and 3 for the 4 month arm.
The Prostate Centre, Vancouver
Manitoba Prostate Centre, Winnipeg
Centre of Clinical Research, Halifax
Northeast Cancer Centre, Health Sciences North, Greater Sudbury
McMaster Institute of Urology, Hamilton
Centre of Applied Urological Research / Kingston General Hospital, Kingston
London Health Sciences Centre, London
URLX Corporation, Ottawa
Sunnybrook Health Sciences Centre, Toronto
University Health Network, Toronto
Recherches Clinique /Clinical Research, Granby
The Urology Specialists / Les Urologues Specialises, Montreal
MUHC Montreal General Hospital, Montreal
Ultra-Med Research, Pointe-Claire
Centre de recherche du CHUQ-L'hotel-Dieu de Quebec, Québec
Collaborators (1)
Ferring Pharmaceuticals
INDUSTRY
Canadian Urology Research Consortium
OTHER